Tyrosine kinase inhibitors response evaluation in phylladelphia positive chronic myeloginous leukemia patients from january 2009 to january 2014 : A retrospective study / Ibraheem Hassan Kabeel ; Supervised Emad Hamada , Mostafa Elhaddad , Moustafa Aldaly
Material type:
- دراسة استعادية لتقييم تأثير الأدوية المثبطة لانزيم التايروزين كاينيز في حالات سرطان لدم الميلودي المزمن موجبة كروموزوم فيلاديلفيا [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.23.M.Sc.2015.Ib.T (Browse shelf(Opens below)) | Not for loan | 01010110068460000 | |||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.23.M.Sc.2015.Ib.T (Browse shelf(Opens below)) | 68460.CD | Not for loan | 01020110068460000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Oncology (Radiation)
The cause of chronic myeloid leukemia is a constitutively active BCR-ABL tyrosine kinase enzyme. Imatinib,Dasatinib and Nilotinib inhibit this kinase .We analyzed the results of response in patients of ph+ve CML who attended Kasr El Aini center of radiation oncology during the period Jan.2009 to Jan 2014 .We analyzed hematologic and molecular response, together with progression free survival and adverse events.Imatinib induced a hematological response in almost all cases, but its molecular response was less. Dasatinib and Nilotinib were used as a second line after Imatinib failure, suboptimal response, or intolerable adverse effects
Issued also as CD
There are no comments on this title.